Australia markets closed

Jeil Pharmaceutical Co.,Ltd (271980.KS)

KSE - KSE Delayed price. Currency in KRW
Add to watchlist
15,190.000.00 (0.00%)
At close: 03:30PM KST
Currency in KRW

Valuation measures4

Market cap (intra-day) 221.34B
Enterprise value 257.54B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.31
Price/book (mrq)1.43
Enterprise value/revenue 0.36
Enterprise value/EBITDA 339.17

Trading information

Stock price history

Beta (5Y monthly) 1.12
52-week change 3-19.25%
S&P500 52-week change 323.20%
52-week high 319,870.00
52-week low 314,540.00
50-day moving average 316,399.80
200-day moving average 316,552.95

Share statistics

Avg vol (3-month) 381.39k
Avg vol (10-day) 311.09k
Shares outstanding 514.57M
Implied shares outstanding 614.67M
Float 85.42M
% held by insiders 162.27%
% held by institutions 12.18%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 450
Forward annual dividend yield 40.33%
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 40.23
Payout ratio 414.58%
Dividend date 3N/A
Ex-dividend date 427 Dec 2023
Last split factor 21.4:1
Last split date 311 Apr 2018

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -1.50%
Operating margin (ttm)-1.28%

Management effectiveness

Return on assets (ttm)-1.22%
Return on equity (ttm)-7.30%

Income statement

Revenue (ttm)705.76B
Revenue per share (ttm)48,430.51
Quarterly revenue growth (yoy)-10.80%
Gross profit (ttm)N/A
EBITDA 629.56M
Net income avi to common (ttm)-10.58B
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)34.7B
Total cash per share (mrq)2,381.19
Total debt (mrq)70.89B
Total debt/equity (mrq)42.32%
Current ratio (mrq)1.03
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)6.36B
Levered free cash flow (ttm)22.24B